Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arbutus Biopharma Corporation (ABUS) stocks in Canada

Learn how to easily invest in Arbutus Biopharma Corporation stocks.

Arbutus Biopharma Corporation is a biotechnology business based in the US. Arbutus Biopharma Corporation stocks (ABUS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.91 – a decrease of 19.03% over the previous week. Arbutus Biopharma Corporation employs 76 staff and has a trailing 12-month revenue of around $10.2 million.

How to buy shares in Arbutus Biopharma Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arbutus Biopharma Corporation stock price (NASDAQ:ABUS)

Use our graph to track the performance of ABUS stocks over time.

Arbutus Biopharma Corporation shares at a glance

Information last updated 2022-01-17.
Latest market close$2.68
52-week range$2.43 - $6.50
50-day moving average $3.71
200-day moving average $3.44
Wall St. target price$6.30
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.92

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Arbutus Biopharma Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Arbutus Biopharma Corporation price performance over time

Historical closes compared with the close of $2.68 from 2022-01-21

1 week (2022-01-14) -19.03%
1 month (2021-12-23) -35.58%
3 months (2021-10-20) N/A
6 months (2021-07-23) -2.90%
1 year (2021-01-22) -33.83%
2 years (2020-01-24) -7.27%
3 years (2019-01-24) 3.51
5 years (2017-01-24) 3.08%

Arbutus Biopharma Corporation financials

Revenue TTM $10.2 million
Gross profit TTM $-40,567,000
Return on assets TTM -28.32%
Return on equity TTM -63.27%
Profit margin 0%
Book value $1.29
Market capitalisation $447.7 million

TTM: trailing 12 months

Arbutus Biopharma Corporation share dividends

We're not expecting Arbutus Biopharma Corporation to pay a dividend over the next 12 months.

Have Arbutus Biopharma Corporation's shares ever split?

Arbutus Biopharma Corporation's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma Corporation shares which in turn could have impacted Arbutus Biopharma Corporation's share price.

Arbutus Biopharma Corporation share price volatility

Over the last 12 months, Arbutus Biopharma Corporation's shares have ranged in value from as little as $2.43 up to $6.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 2.6579. This would suggest that Arbutus Biopharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arbutus Biopharma Corporation overview

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc. ; Alnylam Pharmaceuticals, Inc. ; Acuitas Therapeutics, Inc. ; and Antios Therapeutics, Inc.

Stocks similar to Arbutus Biopharma Corporation

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site